Citation Impact
Citing Papers
Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes
2015 Standout
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
Non-alcoholic fatty liver and the gut microbiota
2016
Confounding factors of non-invasive tests for nonalcoholic fatty liver disease
2020
From NASH to HCC: current concepts and future challenges
2019
Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C
2011
Accuracy of Risk Scores for Patients With Chronic Hepatitis B Receiving Entecavir Treatment
2013
Limitations of non-invasive tests for assessment of liver fibrosis
2020
Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease
2016
Nonalcoholic fatty liver disease and aging: Epidemiology to management
2014
Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis
2013
Non-alcoholic fatty liver disease – A global public health perspective
2018 Standout
Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients With Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus DNA
2014
Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B
2013
New trends on obesity and NAFLD in Asia
2017
Hepatocellular carcinoma
2016 Standout
Hepatocellular carcinoma
2018 Standout
Non-alcoholic fatty liver disease with and without metabolic syndrome: Different long-term outcomes
2016
Nonalcoholic Fatty Liver Disease in Lean Individuals in the United States
2012
Burden of liver diseases in the world
2018 Standout
Prevalence and Risk Factors for the Development of Nonalcoholic Fatty Liver Disease in a Nonobese Chinese Population: the Zhejiang Zhenhai Study
2013
Entecavir improves the outcome of acute-on-chronic liver failure due to the acute exacerbation of chronic hepatitis B
2013
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
2017 Standout
Prevalence of Nonalcoholic Fatty Liver Disease in the United States: The Third National Health and Nutrition Examination Survey, 1988–1994
2013
MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice
2016
Inverse Association between Hepatitis B Virus Infection and Fatty Liver Disease: A Large-Scale Study in Populations Seeking for Check-Up
2013
The changing epidemiology of liver diseases in the Asia–Pacific region
2018
Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver
2016
Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection
2011
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
2022
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
2015 Standout
Targeting oxidative stress in disease: promise and limitations of antioxidant therapy
2021 Standout
Risk Assessment of Hepatitis B Virus–Related Hepatocellular Carcinoma Development Using Liver Stiffness Measurement (FibroScan) σ
2010
Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy
2015
Nonalcoholic fatty liver disease in Asia: emerging perspectives
2016
Hepatocellular carcinoma
2021 Standout
A global view of hepatocellular carcinoma: trends, risk, prevention and management
2019 Standout
Incidence of non-alcoholic fatty liver disease in Hong Kong: A population study with paired proton-magnetic resonance spectroscopy
2014
The role of quantitative hepatitis B surface antigen revisited
2016
Use of Liver Imaging and Biopsy in Clinical Practice
2017
Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?
2015
Baseline characteristics and early on-treatment response predict the outcomes of 2years of telbivudine treatment of chronic hepatitis B
2009
Bariatric Surgery Improves Histological Features of Nonalcoholic Fatty Liver Disease and Liver Fibrosis
2014
Treatment of NAFLD with diet, physical activity and exercise
2017
Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease
2011
HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability
2013
Validation of the HCC‐MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy
2008
From NAFLD in clinical practice to answers from guidelines
2013
Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease
2014
Hepatic Gene Expression Profiles Differentiate Presymptomatic Patients With Mild Versus Severe Nonalcoholic Fatty Liver Disease
2013
Non invasive evaluation of portal hypertension using transient elastography
2011
Virus associated malignancies: The role of viral hepatitis in hepatocellular carcinoma
2014 StandoutNobel
Mechanisms of NAFLD development and therapeutic strategies
2018 Standout
Liver Stiffness Measurement by Transient Elastography as a Predictor on Posthepatectomy Outcomes
2012
Nonobese Fatty Liver Disease
2016
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
2016 Standout
Noninvasive biomarkers in NAFLD and NASH — current progress and future promise
2018
Sex and gender: modifiers of health, disease, and medicine
2020 Standout
Portal hypertensive bleeding in cirrhosis
2016 Standout
Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers
2012
Non-alcoholic fatty liver disease
2021 Standout
Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial
2013
Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography
2011
Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults
2011 Standout
Predictors of survival in hepatitis B virus related decompensated cirrhosis on tenofovir therapy: An Indian perspective
2013
Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B
2011
Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population
2014
The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis
2015
A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver
2013
Hepatic and Cardiac Steatosis
2012
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
2013
Chronic hepatitis B: Update 2009 #
2009 Standout
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
2012 Standout
A Liver Stiffness Measurement-Based, Noninvasive Prediction Model for High-Risk Esophageal Varices in B-Viral Liver Cirrhosis
2010
Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-Related Death in Men With Chronic Hepatitis B: A Large Cohort Study
2017
American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases
2017
Optimal management of hepatitis B virus infection – EASL Special Conference
2015
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
2016
Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report
2011
Radiologic evaluation of nonalcoholic fatty liver disease
2014
Hyponatremia and Mortality among Patients on the Liver-Transplant Waiting List
2008 Standout
Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis
2016
Vitamin E and changes in serum alanine aminotransferase levels in patients with non‐alcoholic steatohepatitis
2013
NAFLD in Asia—as common and important as in the West
2013
Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis
2018
What We Talk About When We Talk About Fat
2014 Standout
Advances in Pediatric Nonalcoholic Fatty Liver Disease†
2009
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
2012 Standout
Prognostic Value of Controlled Attenuation Parameter by Transient Elastography
2017
Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients
2016
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
2015 Standout
Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis
2016
The Natural History of Nonalcoholic Fatty Liver Disease—An Evolving View
2017
Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: a Systematic Review of Liver Biochemistry and Histology
2015
Extrahepatic complications of nonalcoholic fatty liver disease
2013
Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up
2012
A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis
2017
Nonalcoholic fatty liver disease: A comprehensive review of a growing epidemic
2014
Molecular aspects of fructose metabolism and metabolic disease
2021
Insulin, glucose and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort
2011
Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: A systematic review
2012
Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies
2014
On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir
2013
Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy
2015
Increased risk of cardiovascular disease and chronic kidney disease in NAFLD
2012
NAFLD: A multisystem disease
2015 Standout
Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease
2016
Fatty liver is an independent predictor of early carotid atherosclerosis
2016
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management
2014
Inflammation in obesity, diabetes, and related disorders
2022 Standout
The model for end-stage liver disease (MELD)
2007
Gut microbiota in human metabolic health and disease
2020 Standout
Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease
2018
Hepatic MR Elastography: Clinical Performance in a Series of 1377 Consecutive Examinations
2015
Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome
2012
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Association of obstructive sleep apnoea with the presence and severity of non‐alcoholic fatty liver disease. A systematic review and meta‐analysis
2013
Hepatocellular Carcinoma
2019 Standout
AASLD guidelines for the treatment of hepatocellular carcinoma
2017 Standout
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
Systematic review with meta-analysis: the diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B
2015
Magnesium in Man: Implications for Health and Disease
2014 Standout
Mechanisms of Insulin Action and Insulin Resistance
2018 Standout
Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
2018 Standout
Ectopic Fat, Insulin Resistance, and Nonalcoholic Fatty Liver Disease
2014
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals
2013
Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study
2020
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis
2017 Standout
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions
2017
Epidemiology of alcoholic and nonalcoholic fatty liver disease in C hina
2013
Development and implementation of a commissioned pathway for the identification and stratification of liver disease in the community
2019
The effect of magnesium supplementation and weight loss on liver enzymes in patients with nonalcoholic fatty liver disease.
2013
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
Discontinuation of oral antivirals in chronic hepatitis B: A systematic review
2016
Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B
2016
Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
2016
Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
2014 Standout
Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 1: Definition, risk factors and assessment
2017
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
2018 Standout
Non-alcoholic fatty liver disease may develop in individuals with normal body mass index.
2012
Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan
2020
Review article: emerging anti‐fibrotic therapies in the treatment of non‐alcoholic steatohepatitis
2016
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
2023 Standout
Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region—the GO ASIA initiative
2018
Serum cytokeratin‐18 in the diagnosis of non‐alcoholic steatohepatitis: A meta‐analysis
2013
Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD
2020
Nonalcoholic Fatty Liver Disease: Pathologic Patterns and Biopsy Evaluation in Clinical Research
2012
Updated thresholds for serum alanine aminotransferase level in a large‐scale population study composed of 34 346 subjects
2012
Inflammatory responses and inflammation-associated diseases in organs
2017 Standout
Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease
2017
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Histologically proven non‐alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation
2014
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
2017 Standout
NAFLD and Chronic Kidney Disease
2016
Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study
2015
Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease
2013
Transient elastography compared to serum markers to predict liver fibrosis in a cohort of C hinese patients with chronic hepatitis B
2014
Nonalcoholic Fatty Liver Disease
2015 Standout
Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients
2013
Screening for non‐alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography
2018
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
2018 Standout
Leptin's Role in Lipodystrophic and Nonlipodystrophic Insulin-Resistant and Diabetic Individuals
2013
Fast detection of liver fibrosis with collagen-binding single-nanometer iron oxide nanoparticles via T 1 -weighted MRI
2023 StandoutNobel
Natural history of NASH and HCC
2020
Hepatic Fibrosis, Inflammation, and Steatosis: Influence on the MR Viscoelastic and Diffusion Parameters in Patients with Chronic Liver Disease
2016
Green tea extract provides extensive Nrf2‐independent protection against lipid accumulation and NFκB pro‐ inflammatory responses during nonalcoholic steatohepatitis in mice fed a high‐fat diet
2015
Works of A. M.‐L. Chim being referenced
Prediction of off-Treatment Response to Lamivudine by Serum Hepatitis B Surface Antigen Quantification in Hepatitis B E Antigen-Negative Patients
2011
Bacterial endotoxin and non‐alcoholic fatty liver disease in the general population: a prospective cohort study
2015
Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HB eA g‐seroconversion in chronic hepatitis B patients at 3 years
2012
Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years
2010
Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B
2007
Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B
2010
Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population
2010
Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease
2011
High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis
2011
Alanine aminotransferase‐based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B
2008
Metabolic and histological features of non‐alcoholic fatty liver disease patients with different serum alanine aminotransferase levels
2008
Evaluation of Model for End-Stage Liver Disease for Prediction of Mortality in Decompensated Chronic Hepatitis B
2006
Non-alcoholic fatty liver disease: Spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study
2013
Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B
2009
Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B
2008
Metabolic syndrome delays HB eAg seroclearance in Chinese patients with hepatitis B
2014
Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B – a prospective cohort study with paired transient elastography examinations
2014
Assessment of non‐alcoholic fatty liver disease using serum total cell death and apoptosis markers
2012
2014